New shot could tame stubborn high cholesterol
NCT ID NCT07421297
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new injectable drug called SYH2053 in 760 adults with high cholesterol or mixed lipid disorders. Participants receive either the drug or a placebo to see if it safely lowers LDL ('bad') cholesterol. The study aims to offer a new treatment option for people who haven't met their cholesterol goals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYH2053 injection
- What this could lead to
- If it works, this could provide a new injectable option to help control high cholesterol and reduce heart disease risk.
- What could go wrong
- This is a Phase 3 trial, but results may not show a meaningful benefit over existing treatments. Side effects or lack of long-term safety data could limit its use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-FAMILIAL HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliation: Peking University Third Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
-
Affiliation: Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.